Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.22.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Cash flows from operating activities      
Net income $ 12,494,000 $ 1,057,000  
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Realized loss on marketable debt securities 179,000 2,000  
Depreciation and amortization 1,249,000 536,000  
Amortization of debt discount 1,000 2,000  
Amortization on right-of-use assets 83,000 85,000  
Gain on sale of assets (23,000)  
Stock-based compensation expense 482,000 428,000  
Change in fair value of investment securities 76,000  
Accounts receivable allowances (924,000)  
Inventory valuation reserve 25,000  
Changes in operating assets and liabilities:      
Accounts receivable 1,938,000 (11,178,000)  
Inventory (105,000) (12,987,000)  
Prepaid and other assets (126,000) 2,243,000  
Other assets 360,000 (8,000)  
Accounts payable and accrued expenses 1,178,000 4,009,000  
Accrued diagnostic services (878,000)  
Deferred revenue 165,000  
Deferred tax liability 443,000  
Lease liabilities (73,000) 101,000  
Income tax payable 2,973,000  
Other liabilities 770,000 7,818,000  
Net cash provided by (used in) operating activities 20,287,000 (7,892,000)  
Cash flows from investing activities      
Issuance of secured promissory note receivable (1,000,000)  
Purchase of marketable securities (206,000) (2,005,000)  
Proceeds from sale of marketable debt securities 5,300,000 100,000  
Proceeds from dispositions of property and other assets 85,000  
Capital expenditures (1,095,000) (3,927,000)  
Net cash provided by (used in) investing activities 4,084,000 (6,832,000)  
Cash flows from financing activities      
Proceeds from issuance of common stock from public offering, net 35,135,000  
Proceeds from issuance of common stock and warrants from private offering 5,500,000  
Repayment of note payable (1,426,000)  
Repurchases of common shares (1,150,000)  
Payment of dividends (4,646,000)  
Net cash (used in) provided by financing activities (7,222,000) 40,635,000  
Increase in cash, cash equivalents and restricted cash 17,149,000 25,911,000  
Cash, cash equivalents and restricted cash, at the beginning of the period 8,658,000 6,816,000 $ 6,816,000
Cash, cash equivalents and restricted cash, at the end of the period 25,807,000 32,727,000 $ 8,658,000
Supplemental disclosures:      
Cash paid for income taxes  
Interest payment on the promissory notes 241,000 250,000  
Supplemental disclosure of non-cash investing and financing activities:      
Issuance of common shares for debt conversion 600,000  
Net unrealized gain (loss), investments in marketable debt securities $ 37,000 $ (11,000)